Functional dissection of inherited non-coding variation influencing multiple myeloma risk.
Loading...
Embargo End Date
ICR Authors
Authors
Ajore, R
Niroula, A
Pertesi, M
Cafaro, C
Thodberg, M
Went, M
Bao, EL
Duran-Lozano, L
Lopez de Lapuente Portilla, A
Olafsdottir, T
Ugidos-Damboriena, N
Magnusson, O
Samur, M
Lareau, CA
Halldorsson, GH
Thorleifsson, G
Norddahl, GL
Gunnarsdottir, K
Försti, A
Goldschmidt, H
Hemminki, K
van Rhee, F
Kimber, S
Sperling, AS
Kaiser, M
Anderson, K
Jonsdottir, I
Munshi, N
Rafnar, T
Waage, A
Weinhold, N
Thorsteinsdottir, U
Sankaran, VG
Stefansson, K
Houlston, R
Nilsson, B
Niroula, A
Pertesi, M
Cafaro, C
Thodberg, M
Went, M
Bao, EL
Duran-Lozano, L
Lopez de Lapuente Portilla, A
Olafsdottir, T
Ugidos-Damboriena, N
Magnusson, O
Samur, M
Lareau, CA
Halldorsson, GH
Thorleifsson, G
Norddahl, GL
Gunnarsdottir, K
Försti, A
Goldschmidt, H
Hemminki, K
van Rhee, F
Kimber, S
Sperling, AS
Kaiser, M
Anderson, K
Jonsdottir, I
Munshi, N
Rafnar, T
Waage, A
Weinhold, N
Thorsteinsdottir, U
Sankaran, VG
Stefansson, K
Houlston, R
Nilsson, B
Document Type
Journal Article
Date
2022-01-10
Date Accepted
2021-12-02
Abstract
Thousands of non-coding variants have been associated with increased risk of human diseases, yet the causal variants and their mechanisms-of-action remain obscure. In an integrative study combining massively parallel reporter assays (MPRA), expression analyses (eQTL, meQTL, PCHiC) and chromatin accessibility analyses in primary cells (caQTL), we investigate 1,039 variants associated with multiple myeloma (MM). We demonstrate that MM susceptibility is mediated by gene-regulatory changes in plasma cells and B-cells, and identify putative causal variants at six risk loci (SMARCD3, WAC, ELL2, CDCA7L, CEP120, and PREX1). Notably, three of these variants co-localize with significant plasma cell caQTLs, signaling the presence of causal activity at these precise genomic positions in an endogenous chromosomal context in vivo. Our results provide a systematic functional dissection of risk loci for a hematologic malignancy.
Citation
Nature communications, 2022, 13 (1), pp. 151 - ?
Source Title
Publisher
NATURE PORTFOLIO
ISSN
2041-1723
eISSN
2041-1723
2041-1723
2041-1723
Collections
Research Team
Cancer Genomics
Myeloma Molecular Therapy
Myeloma Molecular Therapy
